Podcasts about Novo Nordisk

GLP-1 drugs like Ozempic and Wegovy are everywhere — but thousands of users now allege the medications caused severe, life-altering injuries including everything from stomach paralysis and colon ruptures to sudden blindness. Drugmakers deny the allegations and say the medications are safe when used as directed. USA TODAY investigative data reporter Austin Fast explains what patients are alleging in court, how widespread GLP-1 use has become and how drug companies like Novo Nordisk and Eli Lilly are responding. Let us know what you think of this episode by sending an email to podcasts@usatoday.com. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We discussed a few things including:  1. Your career journeys 2. Gitte's biotech venture 3. Garnet's venture capital firm 4. Discuss effects of federal policies on innovation ecosystem 5. Discuss outlook for 2026  Garnet Heraman is a serial entrepreneur and investor with 25 years experience at the intersection of innovation + technology. Originally from the island nation of Trinidad & Tobago, he was educated at Columbia University (BA), NYU (MBA) and The London School of Economics.  As a dotcom entrepreneur Garnet had 3 exits, 1 of which was to a publicly traded company. As an investor, he is co-founder and managing partner of Aperture® Venture Capital, a seed stage fintech fund backed by 7 different Fortune 500 corporations.  He is also an LP in other VC funds such as NY InsurTech Fund II and the Berkeley Skydeck Fund, as well as a prolific angel investor. Garnet is highly sought after as a startup technology expert, appearing in over 30 business publications and at events on 5 continents.  ------ Gitte Pedersen is a scientist, CEO, company builder, and investor with a mission to improve health and sustainability. RNA enthusiast. Focused on helping cancer patients survive through better diagnostics and treatment navigation tools.  Serial entrepreneur. Advised several small and medium-sized biotech companies and the Danish Ministry of Foreign Affairs, bringing in +$1B deals to Danish Biotech companies. Advised the European Commission on evidence-based innovation and investment policies.  Won numerous prizes and awards and raised $8M+ in grants. Worked at Novo Nordisk in several management positions, inventing, developing and bringing multiple products to market worldwide. #podcast #AFewThingsPodcast

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world's largest privately held pharma companies, Brian Hilberdink's journey is anything but conventional. Live from JPM 2026 in San Francisco, Biotech 2050 host Alok Tayi sits down with the President, U.S. Human Pharma at Boehringer Ingelheim to explore how frontline sales experience shaped a career now steering launches across obesity, chronic kidney disease, oncology, and rare disease. The pair dive into Boehringer's long-term, privately held model—one that reinvests nearly 30% of revenue into R&D—and the strategic thinking behind its ambitious pipeline: first-in-class breakthroughs in interstitial lung disease, major obesity programs, and upcoming waves of launches through 2027 and beyond. They also unpack the future of commercial pharma—from direct-to-consumer models and digital patient engagement to AI-powered launches and trial recruitment—plus Brian's candid views on China's innovation engine and the growing importance of rare disease. A masterclass in modern pharma leadership, portfolio strategy, and building for generations. Biography: Brian Hilberdink is an accomplished global executive with over 25 years of leadership experience in the pharmaceutical industry, currently serving as President of U.S. Human Pharma at Boehringer Ingelheim. In his role at Boehringer, he oversees several business units across multiple therapeutic areas, including cardiometabolic and renal diseases, obesity, pulmonary fibrosis (ILD), and oncology. Renowned for driving impactful results and fostering cultures of accountability and engagement, Brian consistently enhances organizational performance. Previously, Hilberdink served as Executive Vice President at LEO Pharma, where he led the North American Region and served as President of the U.S. affiliate, which became the primary growth driver for the company globally.. Earlier in his career, Hilberdink held several senior-level positions at Novo Nordisk, where he worked across multiple geographies. He was recognized for developing and executing innovative go-to-market strategies, resulting in the successful launch of multiple blockbuster therapies in the areas of obesity and diabetes.

In this episode, Bethanie Stein, PharmD, Segment President of Pharmacy at Humana, discusses how employers are approaching GLP-1 coverage and why partnerships with manufacturers like Eli Lilly and Novo Nordisk matter now. She shares how CenterWell Pharmacy is using transparency, clinical oversight, and adherence focused models to expand access while managing costs.

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI?  Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

The Food and Drug Administration on recently approved a pill version of Wegovy, Novo Nordisk's blockbuster weight loss drug. The Wegovy pill, as it's called, is first oral version of a GLP-1 drug that has been brought to market for weight loss. A second pill, from Eli Lilly, is also expected to be approved in the coming months. Nicolette M. Pace, a Registered Dietician, Chef, & Nutritionist, is here to talk about all this and more!

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über neue Hoffnung bei Novo Nordisk, Quanten-Angst beim Bitcoin und einen Erfolg für Bayer. Außerdem geht es um Micron, Worthington Steel, Klöckner & Co., Eli Lilly, Viking Therapeutics, Meta, Alphabet, Microsoft, Amazon, BMW, Maersk, Legrand, Nvidia, Tesla, den iShares MSCI World Energy Sector (WKN: A2PHCF), den Xtrackers MSCI World Energy (WKN: A113FF), den VanEck Uranium and Nuclear Technologies (WKN: A3D47K), den Xtrackers FTSE Vietnam Swap ETF (WKN: DBX1AG) und den VanEck Vietnam ETF (WKN: A2AHKE). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Market update for January 16, 2026Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In Today's Episode:Zaid quoted in the WSJ: “he just has aura”Eli Lilly and Novo Nordisk hit with antitrust lawsuitNetflix expands its Sony Pictures deal and pushes further into video podcastsEnergy stocks slide after the White House unveils a plan to stop power bills from going upFun fact of the day: Wall Street banks posted a record $134 billion in trading revenue (while still cutting thousands of jobs)

At the 2025 Medical Innovation Olympics, a powerful all-star expert panel moderated by Melissa Norcross (Vice President, Corporate Strategy, Hyland Software) featuring Eddie Power (CEO, Empower Medical, former Global Medical Affairs Leader at Pfizer), Vivek Mukhatyar (Senior Director, Medical AI Team Lead, Pfizer), and Ravi Kiran Koppichetti (Senior Analyst, Manufacturing Technology, Vertex; former Lead IT Data Engineer, Novo Nordisk) cut through the hype and delivered a practical playbook for leaders in healthcare: 1) Fall in love with the problem, not the tool; 2) Think in systems, not silos; and 3) Train your people, not just your models.Timeline00:00 Highlight 1: Why AI Innovation Fails When the Problem Is Mis-framed01:20 Highlight 2: Probable vs Precise Decisions: Where AI Helps vs Where Governance Must Lead03:38 Highlight 3: Falling in Love with the Problem, Not the Solution04:38 Highlight 4: Non-Patient AI Use Cases: Process, Partnership & Proof06:00 Leadership in the Age of AI: Framing the Right Questions08:52 Systems Thinking in Healthcare Innovation (Hepatitis C Case Study)11:35 Constraints in Medical Affairs: Where Humans Must Stay in the Loop13:19 AI as “Intelligence on Tap” vs Clinical Decision Authority17:53 Defining Target Conditions and What “Done” Really Means20:15 Systems Failures in Real-World Healthcare Environments22:50 How Providers, Payers, and Pharma Are Using AI Today25:47 Who Decides: Human vs AI Agents in Regulated Healthcare27:18 Industry 4.0 Explained: Integrating OT and IT in Pharma Manufacturing30:33 Data Quality, Trust, and Why Most Organizational Data Is Unstructured32:03 Probabilistic AI vs Precision Decisions: A Leadership Framework34:35 Trust, Evaluations, and Human-in-the-Loop AI Design39:11 Why 95% of AI Pilots Fail — and the Role of AI Ambassadors43:08 Closing Reflections: Systems Thinking, Learning Loops, and Fearless Curiosity

One in four people have fatty liver disease... and most don't even know it. In this powerful episode of My Weight Live, Dr. Joshi breaks down who should be screened, how liver health and weight are connected, the early warning signs, the treatments available and the simple lifestyle changes that can lead to better health.This podcast was sponsored by Novo Nordisk Canada. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.The medical information in My Weight - What to Know's content is provided as an information resource only. The content is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice or treatment.All content of this channel is owned by What To Know, LLC. and is protected by worldwide copyright laws. You may download content only for your personal use (i.e., for non-commercial purposes) but no modification or further reproduction of the content is permitted. The content may otherwise not be copied or used in any way.My Weight - What to Know ©️ 2026

Broadcast from KSQD, Santa Cruz on 1-08-2026: Dr. Dawn concludes her 2025 medical advances recap, noting that while GLP-1 weight loss drugs showed unexpected benefits for addiction, schizophrenia, and dementia risk, Novo Nordisk recently reported semaglutide had no effect on cognition in people with existing dementia or mild cognitive impairment. She describes the first successful human bladder transplant performed on May 4th. The 41-year-old recipient received both kidney and bladder due to the bladder's complex blood vessel network. Surgeons practiced on cadavers with active circulation before achieving success, opening pathways for future bladder-only transplants for the 84,000 Americans diagnosed with bladder cancer annually. An emailer follows up about purslane for cognitive health. Dr. Dawn reviewed the referenced studies and found neither actually supported claims about purslane and cognition—one discussed the Lyon Heart Study's Mediterranean diet, the other described antioxidant properties. She cautions listeners that websites citing "scientifically proven" claims often reference articles that don't support their assertions. An emailer asks about statin alternatives after developing severe muscle pain on both atorvastatin and rosuvastatin. Dr. Dawn suggests he shouldn't be on statins given his classic adverse reaction. She recommends ezetimibe plus oat bran for cholesterol, metformin for his elevated triglycerides indicating insulin resistance, and checking LDL particle size and inflammation markers. She emphasizes that cholesterol is a risk factor, not a disease, and treating 50 low-risk people for 10 years prevents only one heart attack. A caller discusses plaque formation theory, comparing it to calluses. Dr. Dawn explains Linus Pauling's similar hypothesis that plaque forms at vessel bifurcations to protect against turbulent blood flow damage. She warns against driving total cholesterol below 130, as it disrupts steroid hormone production. The caller shares his mother's near-fatal rhabdomyolysis from statins—muscle breakdown releasing myoglobin that clogs kidneys—and criticizes data transfer failures between hospital systems. An emailer reports four UTIs in two months at age 79. Dr. Dawn questions whether all were true infections, since vaginal contamination causes false positives on dipstick tests. For confirmed UTIs, she recommends D-mannose and cranberry to prevent bacterial adhesion, post-void residual ultrasound to check for incomplete emptying, lactobacillus probiotics, and vaginal DHEA (Intrarosa) to restore mucosal thickness and disease resistance. Dr. Dawn describes Stanford's Phase III trial for dystrophic epidermolysis bullosa, where defective collagen-7 causes skin layers to separate at the slightest touch. Researchers take patient skin biopsies, use retroviruses to insert corrected genes, grow credit-card-sized skin grafts over 25 days, then suture them onto wounds. At 48 weeks, 65% of treated wounds fully healed versus 7% of controls. She reports a Stanford study showing premature babies who heard recordings of their mothers reading for 2 hours 40 minutes daily developed more mature white matter in language pathways. The left arcuate fasciculus showed greater development than controls, demonstrating how early auditory stimulation shapes brain circuitry even in NICU settings. Dr. Dawn concludes with tattoo safety concerns. Modern vivid inks contain compounds developed for car paint and printer toner, including azo dyes that break down into carcinogenic aromatic amines—especially during laser removal. Pigment particles migrate to lymph nodes and persist in macrophages, causing prolonged inflammation. She advises those with tattoos to avoid laser removal, wear sunscreen, practice lymphatic hygiene, and reconsider extensive new tattoos.

In this episode of the Dividend Talk podcast, we review the performance of their Community Dividend Growth Portfolio, discuss Novo Nordisk's news, the Rio Tinto & Glencore Merger, Terry Smiths Fundsmith annual shareholder letter, and much more.And as always, they answer many questions from the community.

Plus: Andreessen Horowitz raises over $15 billion across several funds. And LG Electronics expects to post a quarterly operating loss for the first time since 2016. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber led off the show with market reaction to the December employment report: Non-farm jobs growth came in lower than expected, up 50,000. The unemployment rate fell to 4.4%. National Economic Council Director Kevin Hassett joined the program with White House reaction to the results. The anchors and Hassett discussed him being in the running for Fed chair, the Supreme Court's upcoming decision on tariffs and what to expect from President Trump's Friday meeting with oil CEOs about reviving production in Venezuela. Also in focus: The stocks surging on Meta's nuclear deals, Amazon's pharmacy to offer Novo Nordisk's Wegovy pill.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We kicked off the program with four news stories and different guests on the stories we think you need to know about!The unsolved murder of Gail Miles…Watertown’s 1st Black police officer.Guest: Emily Sweeney – Boston Globe Cold Case Files reporter Why do most people fail to keep financial resolutions every year? How to reprogram your money mindset and stop wasting your hard-earned cash!Guest: Dr. Willie Jolley - award-winning speaker and best-selling author - here to discuss his new book, Rich Is Good, Wealthy Is Better! Homeowner Side Hustle: Americans Turning Backyards Into Big Bucks w/ Tiny-Home or ADU (accessory dwelling unit). Why are so many people interested in Tiny Homes and how are they making money off of them?Guest: Jon Grishpul – Co-CEO of MaxableSpace.com The approval of the first weight loss pill…FDA approves Wegovy weight loss pill from Novo Nordisk. What to know…Guest: Dr. Richard Siegel - Co-director of the Diabetes and Lipid Center at Tufts Medical Center & Endocrinologist at Tufts Medicine Weight + Wellness – StonehamSee omnystudio.com/listener for privacy information.

Asia Bureau Chief Jing Yang joins TITV Host Akash Pasricha to discuss exclusive reporting on DeepSeek's new V4 flagship model and its superior coding capabilities. We also talk with Cory Weinberg about Strava's confidential IPO and Lambda's $350M raise, and Every CEO Dan Shipper about how AI is blurring the lines between media and software. Then, Ro CEO Zach Reitano breaks down the launch of a new GLP-1 pill with Novo Nordisk and AI's role in modern healthcare. Lastly, we dive into the Silicon Valley obsession with biological age with Jemima McEvoy and the AI shopping race with Editors Martin Peers and Meredith Mazzilli.Articles discussed on this episode: https://www.theinformation.com/articles/deepseek-release-next-flagship-ai-model-strong-coding-abilityhttps://www.theinformation.com/articles/silicon-valley-obsessed-biological-age-tests-despite-dubious-sciencehttps://www.theinformation.com/articles/nvidia-backed-cloud-provider-lambda-talks-raise-350-million-ahead-ipohttps://www.theinformation.com/articles/strava-filed-confidentially-ipo-hired-goldman-sachsTITV airs on YouTube, X and LinkedIn at 10AM PT / 1PM ET. Or check us out wherever you get your podcasts.Subscribe to: - The Information on YouTube: https://www.youtube.com/@theinformation- The Information: https://www.theinformation.com/subscribe_hSign up for the AI Agenda newsletter: https://www.theinformation.com/features/ai-agenda

January 8, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Trump administration releases new dietary guidelines backed by HHS Secretary RFK Jr., recommending avoidance of ultra-processed foods and added sugars while endorsing red meat and full-fat dairy Eli Health unveils instant saliva-based tests for testosterone and progesterone at $8 per test, with results in minutes and Q1 rollout ahead Mark Mastrov and LongRange Capital reacquire 24 Hour Fitness, with plans to upgrade clubs for strength and recovery while preparing for international growth Smart ring shipments jumped 50% in 2025, outpacing smartwatches as Oura explores digital IDs and payments beyond health tracking Novo Nordisk's Wegovy pill launches nationwide as first oral GLP-1 for weight loss at $149/month through pharmacies and telehealth providers More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

Do you suffer from Proctalgia fugax?Today is National Pass Gas Day! - https://nationaltoday.com/national-pass-gas-day/First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. - https://www.cnbc.com/2026/01/05/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-us.html‘Delco Pooper' ordered to undergo anger management and do community service - https://www.nbcphiladelphia.com/news/local/delco-pooper-senteneced/4320774/Follow The Rizzuto Show Daily Comedy Show → https://linktr.ee/rizzshowConnect online → https://1057thepoint.com/RizzShowHear The Rizz Show daily on the radio at 105.7 The Point | Hubbard Radio in St. Louis, MO See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In recent years, we have seen tremendous growth not just in the popularity of anti-obesity medications, but also in the medications themselves, how effective they are, how many there are. What exactly has changed during this rapid evolution? How safe and effective are these medications today? What challenges still exist in using them? To help answer these questions, host Aaron Lohr speaks with Gitanjali Srivastava, MD, professor of medicine, medical director of Vanderbilt Obesity Medicine, and founding program director of the Obesity Medicine Fellowship at Vanderbilt University Medical Center. Dr. Srivastava presented at the Endocrine Society’s Obesity Fellows Conference in September 2025. The title of her presentation was “Pharmacological Approaches to Treating and Understanding Complicated Obesity.” Listening to this episode can earn you 0.5 ABIM MOC points and 0.5 AMA PRA Category 1 credits. If you are interested in those points and credits, you will need to take a pre-test on the Endocrine Society Center for Learning before listening to this episode. You can find a link in this episode’s show notes. After that pre-test, listen to this episode in the Center for Learning, then take the post-test. This episode is made possible by educational grants from Lilly and Novo Nordisk. Show notes are available at https://www.endocrine.org/podcast/enp109 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über en Superzyklus bei Speicherchips, ein Double Downgrade bei Adidas und Comeback-Hoffnung bei Novo Nordisk. Außerdem geht es um Bitcoin, Ether, Western Digital, Seagate, Micron Technology, Samsung, Sandisk, SK Hynix, Nanya Technology, Nvidia, Johnson Controls, Trane Technologies, Carrier Global, Tesla, Eli Lilly, Ventyx Biosciences, Infineon, STMicroelectronics, Aixtron, SAP, Adidas, Nike, Asics, Puma, JD Sports, Novo Nordisk, Wisdom Tree Strategic Metals and Rare Earths Miners (WKN: A3EKKT), MP Materials, Lynas Rare Earths, Northam Platinum Holdings, Taseko Mines, Aurubis, VanEck Rare Earth and Strategic Metals (WKN: A3CRL9), PLS Group, Albemarle, China Northern Rare Earth, MP Materials, BNP Paribas Copper ETC (WKN: PB8C0P), Global X Copper Miners UCITS ETF (WKN: A3C7FZ), Sprott Pure Play Copper Miners (WKN: A3EWMH), Copper Miners ETF (WKN: A3ECC3), Freeport-McMoRan und Southern Copper. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine. We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry. First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the data actually showed, why the comparison was misleading, how trial design and dosing matter, and why Phase 1 results should never be treated as superiority claims. Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk. We discuss how this pill differs from compounded oral semaglutide, why its pricing strategy is so disruptive, and what this launch means for people who have avoided injectable medications. We also explore how direct-to-consumer access, telehealth partnerships, and retail pharmacy distribution signal a broader shift in how obesity care is being delivered. Finally, we address the most ironic—and uncomfortable—story of the week: manufacturing quality concerns involving branded Wegovy pens, reported to include biological particulate matter, at the same time Novo Nordisk continues a years-long public and legal campaign against compounded GLP-1 medications on safety grounds. We discuss FDA inspection history, the acquisition of Catalent, and why credibility depends on consistency—especially when millions of patients are paying close attention. This episode isn't anti-pharma or pharma-friendly. It's patient-first. And it asks a simple question: Who do we trust when science, marketing, access, and manufacturing all collide at once? Episode Timestamps 00:00 — Why this first episode of 2026 matters 02:10 — Hair found in Wegovy pens and why patients notice hypocrisy 06:15 — Arrowhead trial headlines vs. what the data actually shows 11:40 — Why tirzepatide dosing and trial design matter 17:30 — What INHBE targeting may actually be good for (and what it's not) 21:45 — Sponsor: SHED and access pathways for obesity care 25:10 — Oral Wegovy officially launches: what's different this time 30:20 — How the Wegovy pill works and why bioavailability matters 35:40 — Pricing, telehealth, Costco, and direct-to-consumer access 41:50 — Why pills lower barriers for millions of patients 46:10 — Manufacturing quality, Catalent, and FDA citations 52:30 — Why safety arguments against compounding are being scrutinized 58:40 — Zooming out: access, accountability, and patient trust 1:02:00 — Final thoughts and what to watch next Topics Covered GLP-1 trial hype vs. real-world context Phase 1 data limitations and headline inflation Tirzepatide dosing and misleading comparisons Oral Wegovy vs. compounded oral semaglutide GLP-1 pill pricing and insurance implications Direct-to-consumer pharma and telehealth disruption Manufacturing quality and FDA oversight Compounding pharmacies and healthcare system resilience Patient trust, transparency, and credibility in obesity medicine Useful Links & Resources On The Pen Links & Advocacy: https://otplinks.com Sponsor – SHED (use code OTP25): https://tryshed.com FDA Drug Safety & Recalls: https://www.fda.gov/drugs Follow On The Pen: YouTube: https://youtube.com/@onthepen Substack: https://onthepen.substack.com Support the Show If this episode helped you better understand what's really happening in obesity medicine: Leave a 5-star rating and review Hit Subscribe so you don't miss future episodes Join us live Mondays, Wednesdays, and Fridays at 12pm Eastern on YouTube Patients deserve clarity. That's what we're here for. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this special live AI edition of the Learning & Development Podcast, David James brings together Egle Vinauskaite, Ross Stevenson, and Peter Manniche Riber for a candid, practical conversation about what AI really means for L&D today. The discussion explores the gap between hype and reality, the tools and applications that are starting to make a meaningful difference and how AI is already being used to improve performance, capability, and skills development. The panel examines what L&D teams are getting right, where major opportunities are being missed and the challenges slowing progress, from security and capability constraints to mindset and organisational conservatism. They also look ahead to how AI could reshape the way L&D operates and how the function is perceived across the business. A clear, grounded and insight-rich conversation for L&D professionals wanting to understand where AI can drive genuine value. KEY TAKEAWAYS AI frees up time and has the capabilities to enable L&D to move beyond courses into solving business problems and improving performance and capability. Real-world examples are shared. AI strategy can't sit with L&D alone; a multidisciplinary, business-driven group must shape it. To stay relevant, L&D needs commercial acumen and tech curiosity, alongside human strengths like storytelling, influence, and relationship‑building. BEST MOMENTS “Too many are just bolting AI onto an existing model, rather than stepping back and saying, does that model still serve us today? ” “We know that content does not equal skills.” “What we really need to do is to target effectiveness. We need to solve the problem.” Egle Vinauskaite Egle Vinauskaite is a learning, behaviour, and technology specialist who works with global enterprises and emerging edtech innovators. With a background across AI, XR, mobile learning, and digital platforms, she brings a sharp perspective on how technology is reshaping organisational learning and the future of work. As both advisor and researcher, she helps L&D teams integrate AI into their operations and equip workforces with the skills needed for effective adoption. https://www.linkedin.com/in/vinauskaite http://nodes.works The Race for Impact report: https://donaldhtaylor.co.uk/research_base/focus04-race-for-impact Ross Stevenson Ross is a leading voice in the global L&D community, known for his practical, no-nonsense approach to modern learning. Through his writing, speaking and community platform Steal These Thoughts, he explores how organisations can better align learning with performance, develop essential skills, and embrace new technologies - including AI. Ross brings a strategic yet pragmatic perspective on how L&D teams can evolve and remain relevant in an age of rapid technological change. https://www.linkedin.com/in/rstevensonuk www.stealthesethoughts.com Peter Manniche Riber Peter is an experienced L&D leader who until recently served as Head of New Tech, Digital Learning Solutions at Novo Nordisk, transforming HR and learning for a global workforce of 70,000+. Passionate about using technology to simplify and enhance learning, he experiments with generative AI, machine learning, adaptive platforms, and data-driven methods to deliver timely, effective solutions. With a strong foundation in team leadership and human-centric design, Peter helps organisations solve business challenges through technology while driving meaningful collaboration and measurable impact. https://www.linkedin.com/in/petermannicheriber RESOURCES L&D Master Class Series: https://360learning.com/blog/l-and-d-masterclass-home HOST CONTACT https://twitter.com/davidinlearning https://www.linkedin.com/in/davidjameslinkedin https://360learning.com/the-l-and-d-collective This Podcast has been brought to you by Disruptive Media. https://disruptivemedia.co.uk/

► Jetzt von der einmaligen Rendite-Spezialisten-Neujahrsaktion profitieren: http://rendite-spezialisten.de/vorteil - 30 Tage Geld-Zurück-Garantie
 Wir starten mit Pauken und Trompeten in das Jahr 2026. Heute möchte ich gemeinsam mit euch einen Deep Dive in Novo Nordisk machen. Es ist kein unrealistisches Szenario, dass sich die Aktie in diesem Jahr verdoppelt oder zumindest mehr als fünfzig Prozent an Wert gewinnt. Wichtig vorab der Disclaimer: Ich bin selbst mit einer Zockerposition investiert und wünsche mir daher, dass genau das eintritt, was ich im Folgenden bespreche.
 ► Hole dir jetzt deinen Zugang zur brandneuen BuyTheDip App! Jetzt anmelden & downloaden: http://buy-the-dip.de
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Meinen BuyTheDip-Podcast mit Sebastian Hell und Timo Baudzus findet ihr hier: https://buythedip.podigee.io
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Zum Zeitpunkt der Erstellung dieses Beitrags war der Autor, Lars Erichsen, in folgenden der besprochenen Finanzinstrumente selbst investiert: Novo Nordisk. Geplante Änderungen: Keine. Weitere Informationen entnehmen Sie bitte unserem Transparenzhinweis zum Umgang mit Interessenskonflikten: https://www.lars-erichsen.de/transparenz-und-rechtshinweis

Today, we're diving into an exciting development in obesity treatment—oral semaglutide.  Last week, the FDA approved Novo Nordisk's Wegovy pill as the first and only oral GLP-1 for weight loss in adults. This approval is based on results from the OASIS-4 phase 3 clinical trial showing that a once-daily oral version of semaglutide can deliver nearly the same weight loss results as the injectable form.  So, what does that really mean for patients and treatment options? Let's break it down. Read the Full Episode Transcript: https://pepties.com/oral-semaglutide/ Dr. Nikki's Qualifications: https://bifat.life/about/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ BioLongevity Labs (Purchase Peptides online) Use our link and enter COUPON CODE: PEPTIDEPODCAST at checkout to receive 15% off your total order https://go.biolongevitylabs.com/aff_c?offer_id=1&aff_id=1582&aff_sub=PEPTIDEPODCAST Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

Looking at a weird GDP data point. Calling BS on Russia/Ukraine peace talks. Gold and Silver – WOW! Closing out the year – a good one too! PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - CTP Cup - All systems go! 9 participants! - Lots to be excited about and anxious too - Looking at a weird GDP data point - Calling BS on Russia/Ukraine peace talks Markets - Gold and Silver - WOW! - Closing out the year - a good one too! - Buyers are still hot to buy any dip - "Diet" pills coming Bitters Making Progress  - Chocolate -Dark Cherry -Infusions - https://highdesertbotanicals.com NYE Celebration - Cities across America ring in the new year by dropping unexpected objects: - Amelia Island, FL drops a giant shrimp. - Nashville drops a 400lb musical note with 28,140 LEDs. - Boise, ID, drops a glowing potato. - Key West, FL, drops an eight-foot ruby-red heel—complete with a drag queen inside! - In Spain, revelers gulp down 12 grapes—one for each midnight chime—to bring luck for each month - Denmark - Danes toss old dishes at friends' doors—large piles of broken crockery at dawn are seen as tokens of good luck. What a year! - So many themes in 12 months - AI, Tariffs, War and Trade War, Fat drugs, Deglobalization - Data centers, semiconductors, and supporting infrastructure like power and cooling systems. - Approx: DJIA +13.5%, SP500 +17%, NASDA +21%, BTCUSD -7.6%, Gold +64%, SLV +145%, $DXY -9.5%, EEM +30% - 2026 - Opportunities and Auld Lang Xiety (Tech still looks frothy in certain names) Top New Year's Resolutions - Exercise More - Eat Healthier - Save More Money/Get Out of Debt - Be Happy/Improve Mental Health - Lose Weight - Spend More Time with Family & Friends - Learn a New Skill/Hobby - Get Organized Active Management (Funds) - Same report annually - A small group of tech super stocks accounted for an outsize share of returns in 2025, extending a pattern in place for the better part of a decade. - Around $1 trillion was pulled from active equity mutual funds over the year, marking an 11th year of net outflows, while passive equity exchange-traded funds got more than $600 billion. - The concentration of gains in a few stocks made it harder for active managers to do well, with 73% of equity mutual funds trailing their benchmarks this year, the fourth most in data going back to 2007. - BUT, there are some areas that it makes sense for active management ---- Equity vs Fixed income and reasoning --- Efficient markets, boots on the ground Fat Pill - The FDA has approved the first-ever GLP-1 pill from Wegovy maker Novo Nordisk. - Novo Nordisk said the starting dose of 1.5 milligrams will be available in early January in pharmacies and via select telehealth providers with savings offers for $149 per month. - The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill. - Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January PowerBall - A ticket sold in Arkansas scored a $1.8 billion Powerball jackpot after Wednesday night's draw — one of the richest lottery prizes in U.S. history, landing just in time for Christmas. - The payout soared after last Monday's drawing produced no winners, with last-minute ticket sales pushing the jackpot to $1.817 billion. That makes it the second-largest U.S. lottery prize ever and the biggest Powerball of 2025, the lottery website said on Thursday. - The winning numbers — 4, 25, 31, 52, 59 and the Powerball 19 - Odds: one in 292.2 million. Silver - Amazing year! - Sunday night futures - >$83 then turned hard lower| - Down 7% on Monday - Range $83 - $71 (15%) for the day - Some rumors about a bank collapse due to wrong way position on Silver - forced liquidation and covering.... ----- Hard to believe that a bank was short that much silver - but..... SoKo Breach - South Korean online retail giant Coupang said it will offer 1.69 trillion South Korean won ($1.17 billion) in compensation to 34 million users affected by a massive data breach disclosed last month. - That is about 4% of Coupang's annual revenue - but a big chunk of their profit - $34 per user NVDA Deal - Nvidia has yet to issue a public announcement or disclosure regarding its $20 billion Groq deal that CNBC was first to cover on Wednesday. - Groq described the deal as a “non-exclusive licensing agreement,” a tool that's been used by tech giants of late in part to avoid regulatory scrutiny. - Analyst: “Antitrust would seem to be the primary risk here, though structuring the deal as a non-exclusive license may keep the fiction of competition alive,” Bernstein's Stacy Rasgon wrote in a report. - Groq will remain an independent company (?) GDP Consumption - Something is a bit off.... - With the marketplace costs increasing, this may be more than a one-off expenditure Q3 GDP Surge Russia/Ukraine - Less that an hour after the White House claimed great movement toward peace - Russian President Putin told President Trump that Russia will revise its negotiating position, raising questions over prospects for peace deal - Russian Foreign Minister Sergei Lavrov says Ukraine tried to attack Russian President Putin's residence - Does anyone even listen to the crap coming out of the White House anymore? - Did you hear Lutnick trying to explain the 600% reduction in costs for pharmaceuticals? Math wizards! - - For 2026, my wish is that they continue to work on the job at hand and just shut up Just for fun - Who is biggest drinker of spirits? - While there's no single official "heaviest drinker," legendary wrestler Andre the Giant is widely cited as having unmatched capacity, famously downing 119 beers in one sitting (or even up to 156 in other accounts) Oil - Crude oil futures down about 9.5% YTD - Much of the drop due to pick up in production (supply/demand) - Still a floor with as Russia, Nigeria, Venezuela etc - What will it take to move up? Best Auto Stock for 2025? - GM! Better than ford, Tesla and others (up 55%) - best year from coming out of bankruptcy in 2009 - Ford up 35% - Mary Barra, CEO selling into the strength - $73 M sold this year (Position down 73% from what she held last year) - - - Barra has contended for years that stock undervalued. With all of these say what does that say now? --- Would she ever say shares are overvalued? More fun stats - A peer?reviewed 2025 study estimates AI data centers (including indirect usage from electricity generation) consumed 312–765 billion liters of water annually. That's more than all bottled water consumed worldwide each year - Direct (on-site) water is used for cooling servers via systems like cooling towers or liquid loops. Indirect (off-site) water stems from electricity generation—particularly from thermal and nuclear plants, which require significant cooling resources - ??? Estimates suggest a single standard AI prompt (about 100 words) is linked to around 1.5 liters of water—accounting for the entire chain of consumption. (This is total usage from cooling powr consumption, electricity generation) - Global AI workloads consumed 50–60 terawatt-hours (TWh) in 2025—roughly the annual electricity use of a medium-sized country like Switzerland. - By 2030, AI-related electricity demand could reach 300–500 TWh annually, according to energy analysts—comparable to the entire electricity consumption of countries like France. Over to Iran - President Trump tells reporters that if Iran is building up its nuclear program, the U.S. will have to "knock them down" again --- Wait - I thought we destroyed all of their nuke aspirations??? - - - AND - Iran's currency hit a record low, triggering wave of protests, according to Bloomberg Fed News - Top Fed Chair Candidate Odds Narrow Again, With Hassett at 43% and Warsh at 35% - President Trump still angry at Powell 0threating to sue for incompetence Odd - Tesla Inc. published a series of sales estimates indicating the outlook for its vehicle deliveries may be lower than many investors were expecting. - The carmaker posted estimates showing analysts on average expect the company to deliver 422,850 cars in the fourth quarter, down 15% from a year earlier. - Tesla is on course for its second consecutive drop in annual vehicle sales, with the company compiling an average estimate for 1.6 million deliveries, down more than 8% from a year earlier. - These are estimates published by analysts - Tesla put on its own site - WHY? End of Year Stat - The U.S. national debt is climbing at a rapid pace and has shown no signs of slowing down despite the growing criticism of massive levels of government spending. - The national debt, which measures what the U.S. owes its creditors, rose to $38,386,384,190,622.68 as of Dec. 30, according to the latest numbers published by the Treasury Department. - That is an increase of about $5.8 billion daily - ~$18 per person in the US per day increase ($7,300) - or about the monthly price of leasing a small Mercedes - Each person in US owes approx $128,000 Love the Show? Then how about a Donation? THE CLOSEST TO THE PIN 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Het was me het jaartje wel op de beurs. DeepSeek, handelsoorlog, herstel van de handelsoorlog... Beurzen beleefden een volatiel jaar, maar bleven toch overeind staan. Deze aflevering maken we de balans voor je op. En we kijken wat er komend jaar in het vat zit. Ook hoor je over het vertrek van een icoon. Warren Buffett staat na de jaarwisseling zijn stoeltje aan het hoofd van Berkshire Hathaway af. Moeten we hem gaan missen? We vertellen je hoe jij je als belegger ook steeds beter moet inlezen in geopolitiek. Want spanningen in Europa, het Midden-Oosten en zelfs tussen de VS en de rest van de wereld regeerden de beurs het afgelopen jaar. En we hebben nog wat laatste nieuws van het jaar. China laat nog even weten dat ze nog altijd ruzie hebben met Nederland als het om de chipindustrie gaat. En Tesla komt op de valreep nog met een slecht vooruitzicht, waar ze waarschijnlijk van hoopten dat het onder de radar door zou vliegen. Te gast: Nico Inberg van De AandeelhouderSee omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über das Abrauschen der Rohstoffe, Nachlässe von Novo Nordisk und den großen Ausblick aufs Börsenjahr 2026. Außerdem geht es um Newmont, AngloGold, Barrick Mining, Freeport-McMoRan, Southern Copper, Dan Ives Wedbush AI Revolution ETF (WKN: A41ALU), Nvidia, Microsoft, Apple, Tesla, Palantir, Crowdstrike, Zalando, Scout24, Rheinmetall, Symrise, SAP, Adidas, Telekom, Siemens Healthineers, Beiersdorf, Amundi MSCI Greece (WKN: LYX0BF). Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Hermann Haller, MD, PhD President, Professor, MDI Biological Laboratory; Professor, Department of Nephrology and Hypertension, Hannover Medical School Haller received his medical degree from the Free University of Berlin and completed his postdoctoral work at Yale University. He has published more than 700 peer-reviewed articles, holds six world-wide patents and has founded four biotech companies. He has received many honors and awards and serves on numerous advisory boards, including those of Bayer, Boehringer Ingelheim, Genzyme and Novo Nordisk. In addition to his position at the MDI Biological Laboratory, he is also a full professor of medicine and former chairman of the Division of Nephrology at the Hannover Medical School in Germany. INNOVATORS is a podcast production of Harris Search Associates.      *The views and opinions shared by the guests on INNOVATORS do not necessarily reflect the views of the interviewee's institution or organization.*

After years of carrying over 300 pounds, Dennis reached out to a physician for help and was able to get a healthier weight. What he found was a new kind of freedom. “Less back pain. Less knee pain. More energy for work, the gym, and playing with my daughter.” In this episode of My Weight Live, Dennis shares what it was like to take control of his health — and how it changed every part of his life.The medical information in this podcast is provided as an information resource only. It is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice and treatment.This episode was sponsored by Novo Nordisk. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.

GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.

The S&P 500 closing at a fresh record high, as commodities come along for the ride. If the metal moves in Gold, Silver, and Copper can keep rocking into the new year, and how this morning's strong GDP report will impact the Fed's next rate decision. Plus Shares of Novo Nordisk on the move as the pharma company's weight loss pill gets approved by the FDA. How the decision can tip the scales for Novo, and what one analyst sees in store for the weight loss drug space.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.

Plus: The U.S. bans new China-made drones from DJI and Autel Robotics, sparking outrage among pilots. And U.S. regulators approve the first GLP-1 weight-loss pill, a tablet formulation of Novo Nordisk's Ozempic and Wegovy. Daniel Bach hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

A surprisingly strong GDP report boosted investors' spirits. Plus: American depositary receipts for Novo Nordisk rise after U.S. regulators approved a pill version of weight-loss drug Wegovy. Danny Lewis hosts. Sign up for the WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA approving the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk. CNBC speaking with the CEO about expanding access and how the pill will increase the company's competitive edge. Then, former U.K. Treasury Minister Jim O'Neill. His outlook for global markets. And President Trump saying “aggressive housing reform” is coming next year. UBS helps look at possible policy changes and the impact to stocks in the sector. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla and Jim Cramer led off show with the weight loss drug wars: Shares of Novo Nordisk shares surged after the FDA approved the company's Wegovy pill — making it the first oral GLP-1 cleared by regulators for treatment of obesity. ServiceNow CEO Bill McDermott joined the program to discuss his company's deal to acquire cybersecurity startup Armis for $7.75 billion in cash. Hear what McDermott had to say about this year's slump in shares of ServiceNow and other software stocks. Also in focus: Q3 GDP shows 4.3% growth, the AI trade, countdown to Christmas and new data on holiday spending, Tesla gets a big price target boost on Wall Street, the stock that's getting a lift from President Trump's battleship announcement. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The US economy picked up speed over the three months to September, as consumer spending jumped and exports increased but consumer sentiment is low, Rahul Tandon hears from a business about what things are like on the ground. The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk. And, an important moment for Indian female cricket players seeing their match fees doubled for domestic games.(Photo: A person shops for products imported from Asia at a market in Los Angeles, California, USA, 07 April 2025. Credit: ALLISON DINNER/EPA-EFE/REX/Shutterstock)

Third quarter growth was much stronger than expected, but low consumer confidence paints a mixed picture. Novo Nordisk shares climb after the FDA approves the first GLP-1 obesity pill. Plus, could space be the place for data centers? Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Wall Street is pushing for another day of gains as stocks aim for a fourth straight win. Key for your money: a busy slate of market-moving data, including a delayed first look at third-quarter GDP. Plus, gold and silver hit fresh all-time highs, — what's driving the 2025 surge. And later, Tesla safety concerns, a Trump bump for a South Korean shipbuilder, and Novo Nordisk pulls ahead in the weight-loss race. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novo Nordisk President & CEO Mike Doustdar discusses the recent US approval of Novo Nordisk's Wegovy weight loss pill, the advantage of being the first to market, the availability of the pill, the company's gameplan, and the timeline of the pill's release. Doustdar spoke with Bloomberg's Katie Greifeld.See omnystudio.com/listener for privacy information.

Broadcast from KSQD, Santa Cruz on 12-18-2025: Dr. Dawn opens by examining how market competition is actually working in the weight loss drug sector. Novo Nordisk's Ozempic and Wegovy compete against Eli Lilly's Monjaro and ZepBound, with prices dropping nearly 50% as companies launch direct-to-consumer websites. The main barriers remain needles and refrigeration, driving development of oral versions. Novo's Wegovy pill awaits FDA approval for early 2026 launch at $150 monthly. Next-generation drugs show remarkable results: Eli's retatrutide causes 24% weight loss in 48 weeks, while Novo's Cagrisema combines semaglutide with amylin to reduce muscle loss. Pfizer paid $10 billion for Metsera's once-monthly drug despite significant side effects. A quick fiber tip suggests adding plain psyllium to morning coffee for cardiovascular and microbiome benefits. Start with half a teaspoon and work up to two teaspoons (10 grams) over several weeks to avoid gas. The prebiotic fiber improves glucose tolerance and may reduce cancer risk. UC San Diego scientists discovered why cancers mutate so rapidly despite being eukaryotic cells with protected chromosomes. The answer is chromothripsis, a catastrophic event where the enzyme N4BP2 literally explodes chromosomes into fragments. These reassemble incorrectly, generating dozens to hundreds of mutations simultaneously and creating circular DNA fragments carrying cancer-promoting genes. One in four cancers show evidence of this mechanism, with all osteosarcomas and many brain cancers displaying it. This explains why the most aggressive cancers resist treatment. Research from 2013 shows any glucocorticoid use significantly increases venous thromboembolism risk, with threefold increases during the first month of use. The risk applies to new and recurrent clots, affecting both oral and inhaled steroids, though IV poses highest risk and topical the lowest. Joint injections fall somewhere between inhaled and oral. Anyone with prior blood clots should avoid steroids except for life-threatening situations like severe asthma attacks requiring ventilation. A meta-analysis of 20 randomized controlled trials shows creatine supplementation helps older adults (48-84) maintain muscle mass when combined with weight training two to three times weekly. The supplement provides no benefit without exercise. Recommended dosing starts at 2 grams and works up to 5 grams daily. Vegans benefit most since they consume little meat or fish. Important caveat: creatine throws off standard kidney function tests (creatinine), so users should request cystatin C testing instead for accurate renal health assessment. A new JAMA study suggesting risk-based mammogram screening is fatally flawed. First, researchers offered chemopreventative drugs like tamoxifen only to the high-risk group, contaminating the study design. Second, the demographics skewed heavily toward white college-educated women, missing the reality that Black women face twice the risk of aggressive breast cancer with 40% higher mortality. Third, wild-type humans failed to follow instructions—low-risk women continued getting annual mammograms anyway while high-risk women skipped recommended extra screenings. The conclusion of "non-inferior" outcomes is meaningless given poor adherence. Stick with annual mammograms, and consider alternating with MRIs for high-risk women. The EAT-Lancet report condemns red meat based purely on observational data showing correlations with heart disease, cancer, and mortality. But people who eat lots of red meat differ dramatically from low consumers: they weigh more, smoke more, exercise less, and eat less fiber. Studies can't control for sleep quality, depression, or screen time. Notably, heavy meat eaters also die more in accidents, suggesting a risk-taking lifestyle phenotype. The inflammatory marker TMAO is higher in meat eaters, but starch is also pro-inflammatory. Eating red meat instead of instant ramen might improve health. A balanced diet with limited amounts beats epidemiology-based blanket statements. Dr. Dawn grades Dr. Oz's performance as CMS administrator. Starting at minus one for zero relevant experience, he earns plus two for promoting diet, exercise, and gut health on his show. He studied intensively after nomination, calling all four previous CMS directors repeatedly and surrounding himself with experienced staff (plus one). He finalized Medicare rules favoring prevention over surgery and earned bipartisan praise as "a real scientist, not radical" (plus one). He divested healthcare holdings but kept some blind trust interests (minus 0.5). He's developing a CMS app and partnering with Google on a digital health ecosystem (plus one), but supports ending ACA subsidies that will raise premiums for millions (minus one). He correctly promoted COVID vaccines and contradicted Trump's Tylenol-autism claims (plus one). Final score: 3.5 out of 5 possible points, the only positive score for any Trump health administrator.

Story of the Week (DR):Embattled BP replaces CEO, naming Woodside Energy chief as first-ever woman leader of a Big Oil giant MMBP names new CEO — its fourth in 6 yearsO'Neill will replace Murray Auchincloss, after less than two years in the role.BP's C-suite milestone: Women in both the CEO and CFO seatsMelody Meyer: Chair of the safety and sustainability committeeDame Amanda Blanc: Senior independent director Interim CEO Carol HowleCFO Kate ThomsonEmma Delaney: EVP, customers & productsKerry Dryburgh - EVP, people, culture & communications and chief human resources and communications officer *Emeka Emembolu: EVP, technology*William Lin - EVP, gas & low carbon energy2 of 8 white dude leadershipEven after Pamela Daley stepped down in July, still 43% female board influenceMeg O'Neill: ‘hard-nosed' outsider who will head BP's pivot away from green energyFirst female appointment to a major oil company has faced fierce resistance from climate activists as boss of Woodside43% female board influence at WoodsideCarol Howle, current executive vice president, supply, trading & shipping of bp, will serve as interim CEO until Meg joins as CEO.BP 'woke' agenda axed as it hires first female chief exec and doubles down on fossil fuelsWarner Bros Discovery board rejects rival bid from ParamountWBD's board of directors (chaired by Samuel Di Piazza Jr.) has unanimously rejected the Paramount tender as inferior and risky, urging shareholders to reject it and uphold the Netflix transaction instead.David Ellison pulled the dad card early onRight after WBD rejected one of multiple secret bids in September, David Ellison called Warner Bros. CEO David Zaslav to request that Zaslav meet with his father, Larry Ellison. The conventional wisdom was that the Oracle cofounder's billions would prevail. In the end, that didn't happen. WBD expressed concern that the bid relied on a revocable trust, whose assets or liabilities were subject to change.A zealous Paramount pulled out all the stops to woo ZaslavWe already knew Zaslav stood to make over $500 million from a Paramount deal, based mainly on his shares that would vest immediately after it closed ($567,712,631, to be exact, according to the filing). Zaslav told the WBD board that the Ellisons had "indicated to him that" if a deal went through, he would "receive a compensation package worth several hundred million dollars," per the filing. Zaslav responded that it "would be inappropriate to discuss any such arrangements at that time," he told the board.Paramount also offered Zaslav the position of co-CEO and co-chairman of the combined company, a role Netflix didn't offer, the filing said.That runs contrary to the narrative put forth in a letter Paramount's attorneys at Quinn Emanuel sent to WBD, stating they suspected the process was biased in favor of Netflix due to WBD leadership's expectations that there could be roles for them at the new company. Paramount's legal and financial advisors didn't know about the "December 3 Quinn Emanuel" letter and, in their view, the letter should not have been sent, was "not helpful," and was a "mistake," the filing says.TikTok signs agreement to create new U.S. joint ventureTikTok has signed binding agreements with investors including Oracle, Silver Lake and MGX for the sale of its US arm, creating a joint venture as part of a deal orchestrated by President Donald Trump.The U.S. joint venture will be 50% held by a consortium of new investors, including Larry Ellison's Oracle, Silver Lake and Abu Dhabi's MGX, with 15% each. Just over 30% will be held by affiliates of certain existing investors of ByteDance, and almost 20% will be retained by ByteDanceHouse Democrats release more Epstein photos, including Bill Gates and a dinner full of wealthy philanthropists Donald TrumpBill Clinton Bill Gates – Microsoft co-founderSergey Brin – Google co-founderRichard Branson – Virgin Group founderLarry Summers – Economist, Harvard President, OpenAI directorSalar Kamangar – Former YouTube CEO Sultan Ahmed bin Sulayem — Emirati businessman; Chair/CEO of DP WorldLes Wexner — Founder of L BrandsLeon Black — co-founder and former CEO of Apollo Global ManagementTom Pritzker — Executive Chair Hyatt HotelsGlenn Dubin — Hedge fund manager Dubin & Co.; co-founder of Highbridge Capital Management Ron Baron — Founder & chairman of Baron Capital ManagementJosh Harris — co-founder of Apollo Global Management and managing partner of Philadelphia 76ers, New Jersey Devils, and Washington CommandersAriane de Rothschild — Wealthy banking heir; CEO of Edmond de Rothschild GroupGoodliest of the Week (MM/DR):DR: Canada to Launch Sustainable Investment Taxonomy in 2026According to the government, the new taxonomy will provide a set of criteria for the identification of investments that are eligible for a “green” or “transition” investment label, enabling companies to issue green or transition bonds, and investors to evaluate the credibility of sustainable investment products.MM: Tesla's having a good time at the DMVCalifornia won the right to ban sales of Tesla vehicles in the state due to false advertising about “self driving cars”MM: Walmart's women truckers surge thanks to $115,000 starting pay and other perks bringing in nontraditional candidatesAssholiest of the Week (MM):Helge LundEmbattled BP replaces CEO, naming Woodside Energy chief as first-ever woman leader of a Big Oil giant:O'Neill is “taking over the British energy behemoth at a time when it has fallen behind the other global oil and gas supermajors and was even a potential takeover target earlier this year by rival Shell.”Is there anything glass cliff-ier than this stat:Helge Lund has now overseen BP's failed Murray Auchincloss tenure, Bernard Looney's tenure, and Bob Dudley's leaving (6 year tenure) and Novo Nordisk's incredible succession failure, the failure of Nokia in 2013… I hate having to celebrate a female first - like becoming a CEO when eminently overqualifiedSam Altman againSam Altman says he has '0%' excitement about being CEO of a public company ahead of a potential OpenAI IPOHe changed it from a non profit to a for profit in order to go public and make all the money.Also: “billionaire says”Sam Altman Sounds Alarm As ChatGPT Explodes Globally: 'Rate Of Change' Sparks AI Anxiety, Job FearsSam Altman Uses His New Image Generator to Show Himself As a Jacked Fireman With Washboard Abs… With an Absolutely Hilarious ErrorSam Altman says OpenAI has gone 'code red' multiple times; and they'll do it againThe “sound the alarm” gaslightPeter C. Earle, Ph.D, Director of Economics and Economic Freedom and Senior Research Fellow at American Institute for Economic Research DRStop Fixating on CEO Pay Ratios and Start Fixing Labor Markets“The average employee is hired under conditions of broad substitutability — many people can competently perform the role with modest training. The CEO labor market is the opposite: extremely small, specialized, global, and contingent on track records that can shift a firm's valuation by billions of dollars. The demand curve for top executive talent is steep; the supply curve is extraordinarily thin.”“Skilled executives can influence strategy, capital allocation, risk management, and organizational culture in ways that affect firm performance far more than incremental labor inputs elsewhere in the organization, even if the latter are voluminous. If a CEO's decisions add even a few percentage points to long-term returns, the economic value created dwarfs the compensation.”Translation: CEOs are worth it, regular workers are not. “Such a ratio also ignores value creation. [...] The relevant question is not “Is the ratio of worker to executive pay too large?” but rather “Does the CEO create more value than their talent costs?”Does not propose how to prove value creation of the CEO other than “stock go up”Earle had this to say about leadership in 2019: “teams (also companies, organizations, groups, and so on) which experience outstanding success inevitably cite leadership as a factor — often the decisive one, and frequently emanating from a particular individual.”“But it should come as no surprise that many successful sports teams, firms, and organizations readily identify leadership as the decisive factor in their triumphs. It's a better story than merely having incredible resources and facilities, superior performance, or as is often the case: simple, garden-variety luck.”Headliniest of the WeekDR: Ryanair CEO Michael O'Leary plans to step down by 2035 & Chipotle chases the protein craze with new menu items — including meat in a cupMM: LinkedIn CEO says it's ‘outdated' to have a five-year career plan: It's a ‘little bit foolish' considering the pace AI is changing the workplaceWho Won the Week?DR: Powerful women at BPMM: 4 year career plansPredictionsDR: David Ellison cancels his Netflix subscription then hires Erika Kirk to run programming at Nickelodeon and MTVMM: Ryanair CEO Michael O'Leary steps down in 2035 and become executive chair, pledging to step down as executive chair in 2057.

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.Background reading: How Ozempic's maker lost its shine after creating a wonder drug.What Trump's new drug pricing deal means for people with obesity.Photo: Sergei Gapon/Agence France-Presse — Getty ImagesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.